News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Masters Speciality Pharma Enters Agreement With ApoPharma



9/4/2014 9:36:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Masters Speciality Pharma signs agreement for the exclusive distribution of Ferriprox® (deferiprone)

UK – 4th September 2014 - Masters Speciality Pharma is pleased to announce a partnership agreement with ApoPharma for the exclusive distribution of Ferriprox® (deferiprone) into India, Pakistan and Sri-Lanka.

Masters has over 29 years experience in the ethical and compliant supply of drugs into countries where an unmet need for the medication exists. Our regulatory authorisation, licenses and capabilities will ensure that through Masters, access is created in the specified countries for those patients’ requiring Ferriprox®.

Ferriprox® is indicated for the treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.

Lawrence Isaacs, Associate Director, Marketing, Sales and Business Development, ApoPharma said “Collaborating with Masters in a drive to distribute the product is essential for us to maximise our efforts to ensure supply across these territories where unmet need exists.”

“If it’s difficult for patients to access suitable treatment it compromises their health in a way that can have serious consequences for their future wellbeing” said Heather Gamble, Business Marketing Director, Masters Speciality Pharma.

In order to obtain access to Ferriprox® (deferiprone) patients or healthcare professionals should contact: Masters Speciality Pharma Email: orders@masters-sp.com Phone: +44 (0)208 327 0900 Fax: +44 (0)208 327 0901 or Online: www.masters-sp.com

For information and interview requests please contact, Lorna Wright, Marketing Communications Manager, on E: lorna.wright@masters-sp.com or T: +44 (0)208 327 0900

About Masters

Masters Speciality Pharma is an international healthcare company, headquartered in the UK, holding all the necessary licenses for international procurement and compliant supply of a comprehensive range of specialty medicines, including controlled drugs. Established in 1984, our expertise and capabilities rest in the worldwide legal importation of innovative pharmaceuticals that are unlicensed, discontinued, are in short supply or orphan drugs for rare diseases into countries where they are unregistered or awaiting approval, which we ethically source through partnerships with a number of world leading pharmaceutical companies.

Masters Speciality Pharma has commercial operations and accredited warehousing in South America, Central America, Europe and the USA. Its multilingual customer services specialists and high performing management teams are led by a strong Executive team and distinguished Board.

For more information about Masters Speciality Pharma, please visit www.masters-sp.com

Ferriprox® (deferiprone)

Ferriprox® is Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved. The product is manufactured to Good Manufacturing Practice (GMP) standards. The product has been commercially available since 1999 and is currently distributed to over 60 countries worldwide.

About ApoPharma

ApoPharma is a drug development company focused on patients suffering from, haematological conditions, neurodegenerative diseases and immune-related conditions. ApoPharma is a member of the Apotex group, the largest Canadian owned pharmaceutical company, which fulfils over 89 million prescriptions annually and export to over 115 countries worldwide.

For more information about ApoPharma, please visit www.apopharma.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
ApoPharma
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES